Android app Apple app link

Here's what Big Pharma could buy in 2025, from obesity drugs to precision cancer treatments, according to a top M&A banker

By Business Insider   |   11 months ago
Here's what Big Pharma could buy in 2025, from obesity drugs to precision cancer treatments, according to a top M&A banker

Big Pharma is set to increase acquisitions in 2025 due to patent expirations on top-selling drugs like Keytruda and Eliquis. Focus areas for acquisitions include obesity, oncology, immunology, and cardiovascular drugs, aiming to fill revenue gaps and capitalize on emerging markets.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.